×
About 22,255 results

ALLMedicine™ Glucagon Center

Research & Reviews  7,230 results

A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Ther...
https://doi.org/10.1007/s12325-022-02223-0 10.1056/NEJM199309303291401 10.1038/labinvest.3700445 10.2337/db08-0061 10.2337/db07-1726 10.1056/NEJM198302173080709 10.1038/ki.1987.174 10.1056/NEJM199311113292004 10.1056/NEJMoa011161 10.1056/NEJMoa011303 10.1056/NEJMoa1811744 10.1056/NEJMoa2024816 10.1056/NEJMoa1616011 10.1001/jama.2018.18269 10.1056/NEJMoa2025845 10.1056/NEJMoa2110956 10.2337/db11-1824 10.1155/2013/248563 10.1016/j.kint.2020.06.024 10.1111/dom.14158 10.1681/ASN.V10122569 10.1161/CIRCULATIONAHA.113.005081 10.1016/j.jdiacomp.2018.04.011 10.1007/s12325-021-01735-5 10.1038/ki.2010.526 10.1016/j.semnephrol.2012.07.010 10.1016/j.jdiacomp.2013.03.003 10.1167/iovs.12-10207 10.1002/2211-5463.12400 10.1038/srep26428 10.1167/iovs.11-8447 10.1126/science.1227166 10.1016/j.cmet.2006.01.004 10.1210/endo.137.7.8770921 10.1681/ASN.2006070778 10.1016/j.mce.2010.04.022 10.1155/2016/1379274 10.1038/s41598-020-62579-7 10.1096/fj.11-202994 10.2337/db13-1029 10.1155/2021/2182225 10.1007/s11906-017-0778-2 10.2174/1574884713666181116100946 10.1186/s12882-016-0337-0 10.1097/FJC.0000000000000366 10.1161/HYPERTENSIONAHA.117.10360 10.1097/FJC.0000000000000091 10.1016/j.ejphar.2021.174583 10.1016/j.heliyon.2022.e08878 10.1161/HYPERTENSIONAHA.116.08526 10.1681/ASN.2016040477 10.1093/eurheartj/eht187
Advances in Therapy; Mima A

Jun 26th, 2022 - Diabetic kidney disease (DKD) is one of the most important diabetic complications. DKD is also the most common cause of chronic kidney disease (CKD) and end-stage renal disease. This review focused on potential therapeutic drugs for which there is...

Obesity-related vascular dysfunction persists after weight loss and is associated with ...
https://doi.org/10.1152/ajpheart.00031.2022
American Journal of Physiology. Heart and Circulatory Phy... Kiernan R, Persand D et. al.

Jun 25th, 2022 - Obesity-related cardiovascular complications are a major health problem worldwide. Overconsumption of the Western diet is a well-known culprit for the development of obesity. While short-term weight loss through switching from a Western diet to a ...

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy
https://clinicaltrials.gov/ct2/show/NCT04883346

Jun 24th, 2022 - This is an open-label Phase II non-randomized pilot study conducted at the NIH Clinical Center to investigate the efficacy of daily subcutaneous injection of liraglutide, a glucagon-like peptide-1 (GLP1) analogue to promote reduction of body mass ...

see more →

Guidelines  4 results

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diag...
https://doi.org/10.1016/j.eprac.2022.03.010
Endocrine Practice : Official Journal of the American Col... Cusi K, Isaacs S et. al.

May 16th, 2022 - To provide evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to endocrinologists, primary care clinicians, health care professionals, and other...

Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-base...
https://doi.org/10.1016/j.kint.2020.06.024
Kidney International; de Boer IH, Caramori ML et. al.

Jul 13th, 2020 - Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease represents the first KDIGO guideline on this subject. The guideline comes at a time when advances in diabetes technology and therapeuti...

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Repor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971782
Diabetes Care; Buse JB, Wexler DJ et. al.

Dec 21st, 2019 - The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials...

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the America...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245208
Diabetes Care; Davies MJ, D'Alessio DA et. al.

Oct 7th, 2018 - The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation ...

see more →

Drugs  79 results see all →

Clinicaltrials.gov  1,002 results

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy
https://clinicaltrials.gov/ct2/show/NCT04883346

Jun 24th, 2022 - This is an open-label Phase II non-randomized pilot study conducted at the NIH Clinical Center to investigate the efficacy of daily subcutaneous injection of liraglutide, a glucagon-like peptide-1 (GLP1) analogue to promote reduction of body mass ...

The Role of Phosphodiesterase Inhibitors in Incretin Secretion
https://clinicaltrials.gov/ct2/show/NCT02363335

Jun 24th, 2022 - Objectives and Specific Aims: We plan to investigate whether phosphodiesterases are involved in the regulation of glucagon-like peptide-1 (GLP-1) secretion from L cells in humans. We hypothesize that: (1) phosphodiesterase-4D (PDE4D) inhibitor (ro...

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
https://clinicaltrials.gov/ct2/show/NCT05254314

Jun 23rd, 2022 - This is a proof-of-principal randomized, double-blind, placebo-controlled, single-site clinical trial of semaglutide in adult (age 18 or older, n=100), obesity-related (BMI≥30), symptomatic asthma without type II diabetes. This study will monitor ...

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outco...
https://clinicaltrials.gov/ct2/show/NCT03993132

Jun 22nd, 2022 - The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1 Receptor Agonists ...

The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans
https://clinicaltrials.gov/ct2/show/NCT04461015

Jun 21st, 2022 - Study A (Insulin 0.4mU/Kg/min): Subjects will be admitted to the CRTU at approximately 1700 on the day prior to study. They will then consume a standard 10kcal/kg meal (55% carbohydrate, 30% fat, 15% protein, caffeine free) and fast overnight. Blo...

see more →

News  584 results

Glucagon Analog Stops Hypoglycemia Faster Than Carbs
https://www.medscape.com/viewarticle/976139

Jun 24th, 2022 - Dasiglucagon, a glucagon analog approved for treating severe hypoglycemia, also appeared to be effective and highly acceptable for patients with type 1 diabetes with nonsevere hypoglycemia in a controlled, crossover study of 24 patients. In the he...

ADA-EASD: More Holistic Approach Needed for Hyperglycemia Management
https://www.medscape.com/viewarticle/975212

Jun 23rd, 2022 - This transcript has been edited for clarity. In the 2022 Management of Hyperglycemia consensus statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), the focus has shifted. Regarding t...

T2D: Meta-analysis suggests superiority of tirzepatide over other glucose lowering therapies
https://www.mdedge.com/type-2-diabetes-icymi/article/255611/diabetes/t2d-meta-analysis-suggests-superiority-tirzepatide

Jun 22nd, 2022 - Key clinical point : In patients with type 2 diabetes (T2D), once-weekly tirzepatide demonstrated dose-dependent superiority on glycemic efficacy vs. placebo, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), and basal insulin, with.

Best Albuminuria Drug for Diabetes Varies by Patient
https://www.medscape.com/viewarticle/976020

Jun 22nd, 2022 - Dr Viktor R. Curovic A one-size-fits-all approach may not be the best way to treat albuminuria in patients with diabetes. Multiple guidelines recommend a renin-angiotensin system (RAS) inhibitor (an angiotensin-converting enzyme inhibitor or angio...

New Advances in Obesity Management, but Challenges Remain
https://www.medscape.com/viewarticle/975096

Jun 20th, 2022 - This transcript has been edited for clarity. My career has really been around clinical research in obesity and diabetes. I was part of the Diabetes Prevention Program, the Look AHEAD study, and the POUNDS LOST study. I helped develop the DASH diet...

see more →

Patient Education  3 results see all →